Table 1.
Patient demographics and infection and treatment history.
| Double-vaccinated patients without natural infection | Double-vaccinated patients with confirmed history of natural infection | |
|---|---|---|
| N | 16 | 14 |
| Female, n (%) | 10 (62.5) | 7 (50.0) |
| Race, n (%) | ||
| White/Caucasian | 14 (87.5) | 12 (85.7) |
| Black/African American | 2 (12.5) | 1 (7.1) |
| South Asian | 0 (0.0) | 1 (7.1) |
| Age, years, mean (SD) | 51.6 (11.5) | 47.6 (16.1) |
| Seroconverted after double vaccination, n (%) | 6 (37.5) | 9 (64.3) |
| Seroconverted after SARS-CoV-2 infection, n (%) | N/A | 13 (92.9) |
| Anti-CD20 therapy, n (%) | ||
| Ocrelizumab | 13 (81.3) | 8 (57.1) |
| Rituximab | 3 (18.8) | 2 (14.3) |
| Ofatumumab | 0 (0.0) | 4 (28.6) |
| Vaccine brand, n (%) | ||
| Moderna | 10 (62.5) | 8 (57.1) |
| Pfizer | 5 (31.3) | 4 (28.6) |
| Johnson & Johnson | 1 (6.3) | 2 (14.3) |
N/A, not applicable; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; SD, standard deviation.